Pune, India, Sept. 05, 2023 (GLOBE NEWSWIRE) -- The global plasma fractionation market size was USD 28.69 billion in 2021, and it is projected to grow from USD 30.64 billion in 2022 to USD 49.61 billion by 2029 at a CAGR of 7.1% by 2029. The global market experienced positive growth as a result of the sharp increase in immunoglobulin demand. The rise in immunodeficiency disorders across the globe is to blame for the rising demand.
The highest market share of this region is attributed to several factors. Some factors include major companies that develop and market technologically advanced plasma-derived therapies and products, contributing positively to the region’s growth. Furthermore, the presence of a maximum number of plasma fractionation centres in the U.S. significantly contributes to market growth.
Key Industry Development:
January 2022: Bio Products Laboratory Ltd. announced that the National Medical Products Administration (NMPA) for China granted the company a license to market ALBUMINEX 25% in China.
Request A Research Sample PDF: https://www.fortunebusinessinsights.com/enquiry/sample/plasma-fractionation-market-101614
Key Takeaways:
- The growth of the plasma fractionation market is being driven by the increasing demand for plasma-derived therapies, the rising prevalence of chronic diseases, and the technological advancements in plasma fractionation.
- The increasing demand for plasma-derived therapies is the major driver of the market growth.
- The key players in the plasma fractionation market are Grifols, S.A., Octapharma AG, CSL Behring GmbH, Kedrion SpA, and Biotest AG.
- The technological advancements in plasma fractionation are also contributing to the growth of the market.
Discover the Leading Players Featured in the Report:
Major players in the plasma fractionation market are CSL (U.S.), Grifols, S.A (Spain), Takeda Pharmaceutical Company Limited (Japan), Kedrion S.p.A (Italy), Octapharma (Switzerland), Bio Products Laboratory Ltd. (U.K.), Biotest AG (Germany), LFB (France).
Report Scope:
| Report Coverage | Details |
| Forecast Period | 2022 to 2029 |
| Forecast Period 2022 to 2029 CAGR | 7.1% |
| 2029 Value Projection | USD 49.61 Billion |
| Base Year | 2021 |
| Market Size in 2022 | USD 30.64 Billion |
| Historical Data for | 2018 to 2020 |
| No. of Pages | 182 |
Browse Complete Report Details: https://www.fortunebusinessinsights.com/industry-reports/plasma-fractionation-market-101614
Drivers & Restraints:
Increasing Demand for Plasma-Derived Medicinal Products to Augment Growth
The market is anticipated to witness significant growth during the forecast period. The launch of new technologies by leading market players is expected to bolster market growth. Also, the rising incidences of immunodeficiency disorders are expected to fuel the market development and expansion during the projected period. Furthermore, surging demand for plasma-derived medicinal products bolstered the market reach in developed as well as developing countries. In addition, the rising awareness about the benefits of plasma-derived products is also contributing to the growth of the market.
Plasma Fractionation Market Restrained by Stringent Regulatory Requirements
The stringent regulatory requirements for plasma fractionation products is a major restraining factor. These products are regulated by government agencies in many countries, and the approval process can be long and expensive. This can make it difficult for new companies to enter the market and for existing companies to bring new products to market. In addition, the high cost of plasma fractionation is also a restraining factor. The cost of collecting, processing, and testing plasma is high, and this can make the products expensive for patients.
However, the emergence of recombinant therapies as an alternative to plasma-derived medicines may hinder market growth.
Report Scope & Segmentation:
By Product
- Albumin
- Immunoglobulin
- Intravenous Immunoglobulin
- Subcutaneous Immunoglobulin
- Coagulation Factors
- Factor IX
- Factor VIII
- Prothrombin Complex Concentrates
- Fibrinogen Concentrates
- Others
- Protease Inhibitors
- Others
By Application
- Immunology & Neurology
- Haematology
- Critical Care
- Pulmonology
- Others
By End-user
- Hospitals & Clinics
- Clinical Research Laboratories
- Others
By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Quick Buy - Plasma Fractionation Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/101614
Protease Inhibitor Segment to Grow Significantly
By product, the market of plasma fractionation is categorized into immunoglobulin, albumin, coagulation factors, protease inhibitors, and others. The protease inhibitors segment is anticipated to dominate the global market due to rising product demand. Also, the immunoglobulin segment is further sub-segmented into intravenous immunoglobulin and subcutaneous immunoglobulin. The coagulation factors are sub-segmented into factor IX, factor VIII, prothrombin complex concentrates, fibrinogen concentrates, and others.
Immunology & Neurology Segment to Lead Market Due to High Adoption of Plasma Proteins
Based on application, the market is segregated into immunology & neurology, haematology, critical care, pulmonology, and others. The immunology & neurology segment holds a dominant market share due to the increasing adoption of plasma proteins.
Hospitals & Clinics to Dominate Global Market Due to its Rising Demand in Medical Procedures
Based on end-users, the market is trifurcated into hospitals & clinics, clinical research laboratories, and others. The hospitals & clinics segment is projected to grow significantly owing to increasing demand for plasma products in numerous medical procedures.
Geographically, the market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
Regional Insights:
North America Holds Dominant Market Share Due to Rising Technical Advancements
North America dominates the global plasma fractionation market share due to increasing technological advancements in the market. The regional market registered USD 16.10 billion in 2021. Furthermore, the presence of leading companies in the market is projected to bolster regional market growth.
Competitive Landscape:
Strategic Acquisition Allows Companies to Propel Growth
The leading market players in plasma fractionation implement different strategies to improve their business performance. The companies form strategic alliances, partnerships, mergers, and acquisitions to expand their business reach and strengthen their market position.
Ask For Customization: https://www.fortunebusinessinsights.com/enquiry/ask-for-customization/plasma-fractionation-market-101614
FAQ’s
How Big Is The Plasma Fractionation Market?
Poultry Diagnostics Market size was USD 30.64 Billion in 2022.
How Fast The Poultry Diagnostics Is Market Growing?
The Poultry Diagnostics Market will exhibit a CAGR of 7.1% during the forecast period, 2022-2029
Related Reports:
India Plasma Fractionation Market Share, Size, Trends and Forecast To 2026
Surgical Robots Market Size, Share, Trends, Growth | Global Forecast Report 2025
Next-generation Sequencing Market Size, Share| Global Forecast Report 2030
Medical Aesthetics Market Trends, Growth | Global Forecast Report 2030
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
Contact Us:
Fortune Business Insights Pvt. Ltd.
9th Floor, Icon Tower, Baner - Mahalunge Road,
Baner, Pune-411045,
Maharashtra, India.
Phone:
US: +1 424 253 0390
UK: +44 2071 939123
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Attachment
